Author Affiliations: Departments of Preventive Medicine and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Dr Greenland is Editor, Archives of Internal Medicine.
The unusual release on January 14, 2008, in the news media and on a drug company Web site,1 of a portion of the Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) trial data resulted in numerous articles and commentaries in the lay media. The availability of only fragmentary information created massive confusion and raised many more questions than answers for patients, physicians,
pharmaceutical companies, and regulators. A full report of the ENHANCE trial in a peer-reviewed medical journal is not expected for months,
and the first public presentation of the study's findings in a medical setting will not occur before late March 2008.
Philip Greenland, Donald Lloyd-Jones. Critical Lessons From the ENHANCE Trial. JAMA. 2008;299(8):953–955. doi:10.1001/jama.299.8.953